Do … NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical, indicating that it is currently the more affordable of the two stocks. 6, 2021, 07:55 PM. About NGM Biopharmaceuticals. NGM Biopharmaceuticals shares have dropped 12% since the beginning of the year. Related party revenue … ... About NGM Biopharmaceuticals, Inc. Mar. NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Tops Revenue Estimates. NGM Biopharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing the next generation of medicines for the treatment of serious diseases. NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -15.15% and -3.25%, respectively, for the quarter ended June 2020. Shares +2% AH. 4, 2021, 07:25 PM. NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.45% and 22.33%, respectively, for the quarter ended March 2020. Zacks . NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -15.15% and -3.25%, respectively, for the quarter ended June 2020. NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. We have built our company around core scientific values that frame our approach to drug discovery and development. Significantly improving liver steatosis, inflammation, and fibrosis. As of May 28th, there was short interest totalling 1,320,000 shares, a drop of 28.3% from the May 13th total of 1,840,000 shares. Related party revenue from our collaboration with Merck for the quarter ended June 30, 2020 was $19.8 million compared to $25.3 million for the corresponding period in 2019. Revenue of $19.77M (-36.4% Y/Y) misses by $1.76M. NGM Biopharmaceuticals … NGM Biopharmaceuticals, Inc is a biotechnology business based in the US. Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc. (NGM) today announced that Merck has exercised its option to license NGM313, an investigational monoclonal antibody agonist of the β-Klotho/FGFR1c receptor complex that is currently being evaluated for the treatment of nonalcoholic steatohepatitis (NASH) and type 2 … In depth view into NGM Biopharmaceuticals PS Ratio explanation, calculation, historical data and more Powerful Biology. We love working together and challenging each other to pursue great science that will deliver a big impact for patients. See insights on NGM Biopharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Specifically, in Q1 2021's revenue was $21.6M; in Q4 2020, it was $19.8M; in Q3 2020, it was $23.5M; in Q2 2020, NGM Bio's revenue was $19.8M. NGM BIOPHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. Get the hottest stocks to trade every day before the … The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share.The biotechnology company posted revenue of $21.6 million in the period, also topping Street forecasts. NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 14.89% and -14.45%, respectively, for the quarter ended December 2020. In the final minutes of trading on Thursday, shares hit $26.75, a rise of 33% in the last 12 months. Dr. Woodhouse became Chief Executive Officer and a member of NGM’s board of directors in September 2018. He previously served as NGM’s Chief Financial Officer, joining the company in March 2015. Want the latest recommendations from Zacks Investment Research? Employees in the top 10 percent can make over $75,000 per year, while employees at the bottom 10 percent earn less than $22,000 per year. MK-3655 is a monoclonal antibody agonist of the b-Klotho/FGFR1c receptor complex. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. Company profile for NGM Biopharmaceuticals Inc. including key executives, insider trading, ownership, revenue and average growth rates. NGM: Get the latest NGM Biopharmaceuticals stock price and detailed information including NGM news, historical charts and realtime prices. NGM438 is a novel antagonist antibody inhibiting LAIR1. NGM is the innovative company that specialized in loyalty management. If you had invested in Ngm Biopharmaceuticals stock at $14.70, your return over the last 2 years would have been 32.31%, for an annualized return of 15.03%. NGM Biopharmaceuticals Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. NGM Bio Provides Business Highlights and Reports Fourth.. 3/02/2021. View detailed NGM description & address. BECOME AN NGM er. NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 14.89% and -14.45%, respectively, for the quarter ended December 2020. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. NGM’s lead compound, NGM282, is in a Phase 2b study for the treatment of PBC. Currently, 5.3% of the shares of the stock are short sold. Revenue: $5 to $10 million (USD) Competitors: UNKNOWN. This compares to year-ago revenues of $31.08 million. The reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.41) by $0.05. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. Do … The Income Statement (earnings report) for NGM Biopharmaceuticals Inc. Find the company's financial performance, revenue, and more. Ngm Biopharmaceuticals Inc () Stock Market info Recommendations: Buy or sell Ngm Biopharmaceuticals stock? Merck Licenses NASH Compound From NGM Biopharma for $20 Million. For the quarter ended September 30, 2020, NGM reported a net loss of $29.8 million, compared to a net loss of $10.9 million for the corresponding period in 2019. * ngm biopharmaceuticals qtrly related party revenue from collaboration with merck was $21.6 million compared to $24.4 million or same period in 2020. NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James 03/31/20 H.C. Wainwright Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright 03/27/20 Citi NGM Biopharmaceuticals price target lowered to $28 from $34 at Citi 02/26/20 B. Riley NGM Biopharmaceuticals price target raised to $30 from $24 at B. Riley FBR 17:20. A high-level overview of NGM Biopharmaceuticals, Inc. (NGM) stock. Our lead product, aldafermin (formerly NGM282), is a first-in-class, engineered variant of the human hormone FGF19 that has demonstrated a rapid regression of liver fibrosis and improvement in liver function by targeting multiple pathogenic pathways of NASH. Our People Are Our Platform. What makes NGM tick? GLOBE. Over the last four quarters, NGM Bio's revenue has grown by 9.2%. NGM Biopharmaceuticals, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $19.77 million for the quarter ended December 2020, missing the Zacks Consensus Estimate by 14.45%. NGM | 1,703 followers on LinkedIn. Dr. Woodhouse became Chief Executive Officer and a member of NGM’s board of directors in September 2018. Four analysts surveyed by Zacks expected $23.1 million. About NGM Biopharmaceuticals, Inc. NGM is a biopharmaceutical company focused on developing novel therapeutics based on scientific understanding of … For the year, the company reported that its loss widened to $102.5 million, or $1.50 per share. Related party revenue from our collaboration with Merck was $21.6 million for the quarter ended March 31, 2021, compared to $24.4 million or the same period in 2020. NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) was the recipient of a significant drop in short interest in May. _____ Want the latest recommendations from Zacks Investment Research? Its shares traded higher over … NGM Bio is a research-driven, clinical-stage biopharmaceutical company with a passion to improve the lives of … It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. Competitive salary. Ngm Biopharmaceuticals stock was originally listed at a price of $14.70 in Apr 4, 2019. The NGM stock’s 52-week price range has touched low of $14.90 and a $32.12 high. Job email alerts. Fact checked. NGM NGM Biopharmaceuticals $16.78 / -11.63 (-40.94%). * qtrly net loss per share, basic and diluted $0.36. NGM Biopharmaceuticals pre-tax profit margin from 2018 to 2021. Revenue fell 11.4% compared to the same quarter a year ago. May. The biotechnology company posted revenue of $19.8 million in the period, falling short of Street forecasts. NGM Biopharmaceuticals (NASDAQ:NGM) Earnings Information. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Ngm Biopharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Ngm Biopharmaceuticals's NGM shares and potentially its market environment have … In comparison, last year the company earned revenue of $24.36 million and had a GAAP net loss of $19.12 million. He previously served as NGM’s Chief Financial Officer, joining the company in March 2015. NGM Biopharmaceuticals Inc. (NASDAQ:NGM) shares, rose in value on Friday, June 11, with the stock price up by 0.94% to the previous day’s close as strong demand from buyers drove the stock to $18.30. High Growth Revenue : NGM's revenue (15.6% per year) is forecast to grow slower than 20% per year. Zacks. NGM Biopharmaceuticals Annual Revenue (Millions of US $) 2020: $87: 2019: $104: 2018: $109: 2017: $77 Revenue vs Market: NGM's revenue (15.6% per year) is forecast to grow faster than the US market (9.3% per year). Verified employers. Merck & Company has licensed NGM313, now renamed MK-3655, from South San Francisco-based NGM Biopharmaceuticals. LAIR1 may form a stromal checkpoint that impedes anti-tumor immunity. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. ... Revenue. Ngm Biopharmaceutica generates negative expected return over the last 90 days: Ngm Biopharmaceutica has high historical volatility and very poor performance: Ngm Biopharmaceutica has high likelihood to experience some financial distress in the next 2 years: The company reported the last year's revenue of 87.37 M.Reported Net Loss for the year was (102.49 M) with loss before taxes, … Analyst Recommendations. NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -15.15% and -3.25%, respectively, for the quarter ended June 2020. The consensus estimate was a loss of $0.42 per share on revenue of $22.5 million. Ngm Biopharmaceuticals (NGM) reported a 1st Quarter March 2021 loss of $0.36 per share on revenue of $21.6 million. The decrease in related party revenue of $16.1 million in 2020 was primarily attributable to a decrease in the recognition of the initial upfront payment received from Merck in 2015 that was included in the transaction price and fully recognized by March 2020. NGM Biopharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. NGM Biopharmaceuticals, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $21.58 million for the quarter … View NGM financial statements in full. NGM Biopharmaceuticals shares (NGM) are listed on the NASDAQ and all prices are listed in US Dollars. In depth view into NGM Biopharmaceuticals Net Margin % explanation, calculation, historical data and more 5, 2021 at 9:20 a.m. NGM Biopharmaceuticals has higher revenue and earnings than Biohaven Pharmaceutical. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. The national average salary for an NGM Biopharmaceuticals employee in the United States is $41,529 per year. NGM Biopharmaceuticals EPS beats by $0.09, misses on revenue. NGM retains an option, at the initiation of the first Phase 3 clinical trial for MK-3655, to participate in up to 50 percent of a global cost and revenue sharing arrangement for MK-3655. In the last year NGM Biopharmaceuticals saw its revenue shrink by 17%. 21.58. Based on NGM Biopharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $21.58 million and GAAP net loss of $27.54 million. Type: Company - Public (NGM) Industry: Biotech & Pharmaceuticals. Mar. NGM Biopharmaceuticals Inc (US:NGM) has 259 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). NGM Biopharmaceuticals Inc. (NASDAQ:NGM) stock’s Relative Strength Index (RSI) is 47.34, with weekly volatility at 4.99% and ATR at 1.38. NGM Biopharmaceuticals last released its quarterly earnings data on May 6th, 2021. NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates. NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (NASDAQ: NGM ), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the period ending March 31, 2021. Learn More. Posted Nov 5, 2020. Institutional Ownership and Shareholders. NGM282 has Company profile for NGM Biopharmaceuticals Inc. including key executives, insider trading, ownership, revenue and average growth rates. Get the latest NGM Biopharmaceuticals Inc (NGM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Do the numbers hold clues to what lies ahead for the stock? The biotechnology company posted revenue of $21.6 million in the period, also topping Street forecasts. NGM Biopharmaceuticals, Inc.is a clinical-stage biopharmaceutical company developing novel therapeutics for the cardio-metabolic, liver, oncologic and ophthalmic diseases. NGM Biopharmaceuticals has 186 employees at their 1 location and $103.54 M in annual revenue in FY 2019. ET by Tomi Kilgore. The top 10 competitors average 1.4B. NGM Biopharmaceuticals General Information Description. Stock analysis for NGM Biopharmaceuticals Inc (NGM:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. NGM Biopharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Press Release. Four analysts surveyed by Zacks expected $21.3 million. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Statement of Changes in Beneficial Ownership (4) NGM Biopharmaceuticals (NGM) shares ended the last trading session 7% higher at $16.20. Chief Executive Officer, NGM Biopharmaceuticals. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth. View detailed NGM description & address. NGM Biopharmaceuticals has generated ($1.50) earnings per share over the last year. NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.45% and 22.33%, respectively, for the quarter ended March 2020. NGM Biopharmaceuticals (NASDAQ: NGM): Q4 GAAP EPS of -$0.40 beats by $0.09. Four analysts surveyed by Zacks expected $21.3 million. Four analysts surveyed by Zacks expected $21.3 million.NGM Biopharmaceuticals shares have dropped 12% since the beginning of the year. Novel Medicines. NGM Bio to Present at the Cowen 41st Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of … Year-over-year growth is forecast to reach 4.8% up from the last financial year. EDGAR. NGM Biopharmaceuticals General Information Description. Free, fast and easy way find a job of 868.000+ postings in San Francisco, CA and other big cities in USA. NGM Biopharmaceuticals employs 210 staff and has a trailing 12-month revenue … ngm biopharmaceuticals inc (ngm): * ngm bio provides business highlights and reports first quarter 2021 financial results. First Quarter Financial Results o … 3/04/2021. NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. The rating firms predict current quarter revenue for NGM Biopharmaceuticals, Inc. will rise +2.6%, while the growth in revenue is estimated to hit 20.9% for the next quarter. … 05/24/21 NGM Biopharmaceuticals trading resumes 05/24/21 NGM Bio plans not to pursue Phase 3 development of aldafermin in F2/F3 NASH NGM Biopharmaceuticals, Inc. and its wholly-owned subsidiary (collectively, referred to as the “Company”) is a biopharmaceutical company focused on developing novel therapeutics based on our scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. Based on an average trading volume of 349,200 shares, the days-to-cover ratio is presently 3.8 days. … Ngm Biopharmaceuticals Inc detailed Quarterly and Annual Revenue year on year Growth Analysis, results, statistics, averages, rankings and trends 2008. Full-time, temporary, and part-time jobs. The company, currently valued at $1.35 Billion, closed the recent trade at $17.71 per share which meant it lost -$10.67 on the day or … 16:05. Search and apply for the latest Director business analysis jobs in San Francisco, CA. The biotechnology company posted revenue of $21.6 million in the period, also topping Street forecasts. NGM Bio's revenue is the ranked 4th among it's top 10 competitors. NGM reported a net loss of $27.5 million for the quarter ended March 31, 2021, compared to a net loss of $19.1 million for the same period in 2020. 9.7. For the quarter ended June 30, 2020, NGM reported a net loss of $25.6 million compared to a net loss of $7.7 million for the corresponding period in 2019. NGM Biopharmaceuticals, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $21.58 million for the quarter … Ngm Biopharmaceuticals (NGM) Recent Earnings. This compares to the stock's 44.3% loss over the past four weeks. NGM Biopharmaceuticals, Inc. and its wholly-owned subsidiary (collectively, referred to as the “Company”) is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. NGM BIOPHARMACEUTICALS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for NGM BIOPHARMACEUTICALS, INC. Stock | NGM | US62921N1054 NGM Biopharmaceuticals stock price target raised to $44 from $27 at Chardan Research. NGM PS Ratio as of today (April 28, 2021) is 22.42. Get the latest NGM Biopharmaceuticals Inc (NGM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. NGM BIOPHARMACEUTICALS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for NGM BIOPHARMACEUTICALS, INC. Stock | NGM | US62921N1054 NGM Biopharmaceuticals is a private biopharmaceutical company using a biology-centric approach to create novel biologics for the treatment of a broad spectrum of life-threatening diseases. Transformative Impact. Do the numbers hold clues to what lies ahead for the stock? NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Tops Revenue Estimates Zacks Investment Research - Wed May 13, 4:35PM CDT Zacks Equity Research - ZACKS - Wed May 13, 4:35PM CDT NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.45% and 22.33%, respectively, for the quarter ended March 2020. Revenue was reported as $87.4 million. These institutions hold a total of 45,813,350 shares. South San Francisco, CA, March 4, 2021 – NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the periods ending December 31, 2020. The agreement also provides NGM with the option to participate in the co-promotion of any co‑funded program in the United States. NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) has a beta value of 0 and has seen 3,989,649 shares traded in the recent trading session. NGM Net Margin % as of today (April 17, 2021) is -141.60%. When a company doesn't make profits, we'd generally expect to see good revenue growth.